50
Participants
Start Date
September 1, 2025
Primary Completion Date
September 1, 2028
Study Completion Date
September 1, 2028
AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients
After chemotherapy, the tumors of the patients in the experimental group were re-graded to determine the basic burden status of the tumors. It should include imaging diagnosis, physical examination, laboratory tests of blood, assessment of bone marrow MRD and evaluation of the toxic and side effects of chemotherapy, etc
RECRUITING
The Affiliated Hospital of Xuzhou Medical University, Xuzhou
The Affiliated Hospital of Xuzhou Medical University
OTHER